

Tepezza Global Market Report 2025: Unveiling Upcoming Growth Opportunities and Trends

*The Business Research Company's
Tepezza Global Market Report 2025 –
Market Size, Trends, And Forecast 2025-
2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, February 10, 2025
/EINPresswire.com/ -- What does the
latest data tell us about the growth
trajectory of the Tepezza market?



The Business
Research Company

Tepezza Market Report 2025 – Market Size, Trends,
And Forecast 2025-2034

Significant growth has been seen in the [Tepezza market size](#) in recent years. It showcased a compound annual growth rate CAGR of XX HCAGR as it grew from \$XX million in 2024 to \$XX million in 2025. A number of contributing factors led to this exceptional growth during the



Updated 2025 Market
Reports Released: Trends,
Forecasts to 2034 – Early
Purchase Your Competitive
Edge Today! "

*The Business Research
Company*

historic period, the increasing prevalence of thyroid eye disease TED, FDA approval for TED treatment, limited treatment options available for TED, a high unmet need for effective therapies, advancements in biologic drug development, and increasing awareness and diagnosis of TED being prominent among them.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20365&type=smp>).

What does the future hold for the Tepezza market?

According to our projections, the Tepezza market size is expected to continue on its growth trajectory in the coming years, with an anticipated compound annual growth rate CAGR of XX FCAGR. The market is forecast to grow to \$XX million by 2029. This forecasted growth should be propelled by a range of factors including a growing aging population, expansion into new geographical markets, an increasing incidence of thyroid diseases, advancements in personalized medicine, and growing adoption of biologic therapies. Besides, there will be some major trends on the horizon during the forecast period such as a shift towards home-based care, development of alternative administration methods, rise in combination therapies for TED,

increased focus on precision medicine, and the integration of AI in treatment planning.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/tepezza-global-market-report>

What's driving the growth of the Tepezza market?

One of the major drivers propelling the Tepezza market growth forward is the increasing incidence of thyroid diseases. These conditions, which affect the structure or function of the thyroid gland, a butterfly-shaped gland located in the neck, are being diagnosed at an increasing rate due to advancements in diagnostic techniques such as high-resolution ultrasound and fine-needle aspiration, which can detect thyroid abnormalities earlier. As a response, the use of Tepezza teprotumumab has become more prevalent. This treatment is designed to inhibit the insulin-like growth factor-1 receptor IGF-1R, reducing inflammation, swelling, and proptosis around the eyes. An example of the growing incidence of thyroid-related illnesses came in July 2022 when the National Institutes of Health reported that thyroid cancer was projected to be the 13th most commonly diagnosed cancer in the United States that year, representing approximately 44,000 new cases or 2.3% of all cancer diagnoses.

Which industry leaders are propelling the Tepezza market forward?

The Tepezza market sees its growth being bolstered by major companies operating within it. A significant player in this sector is Amgen Inc., which has been instrumental in contributing to the evolution and innovation in this market.

What's the latest trend in the industry?

The growing adoption of Tepezza teprotumumab-trbw can be attributed to continuous efforts to expand its indications beyond Thyroid Eye Disease TED. The drive to gain regulatory approvals, which refer to formal authorizations from health agencies attesting to a drug's safety, efficacy, and quality for specific medical uses, is a notable trend in the market. Illustratively, in April 2023, Horizon Therapeutics plc, an Ireland-based biotechnology company, announced an update to the indication language for TEPEZZA teprotumumab-trbw, thanks to FDA approval. This change enables TEPEZZA's use in all eligible TED patients, irrespective of the disease's activity or its duration, making Tepezza the first and only FDA-approved medication specifically for this condition.

How is the global Tepezza market segmented?

The Tepezza market report segments the market based on various factors including:

- 1 By Clinical Indication: Thyroid Eye Disease TED; Orbital Inflammatory Diseases; Inflammatory Ocular Conditions
- 2 By Route Of Administration: Intravenous; Subcutaneous
- 3 By Distribution Channel: Hospital Pharmacies; Online Pharmacies
- 4 By End User: Adult; Geriatric

What is the regional distribution of the Tepezza market?

North America emerged as the largest region in the Tepezza market back in 2024. While other regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Browse Through More Similar Reports By [The Business Research Company](#):

Insulin biosimilars Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report>

Insulin Patch Pumps Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report>

Insulin Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report>

Learn More About The Business Research Company

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our impressive resource of 1,500,000 datasets, in-depth secondary research, and unique insights from industry leaders equip you with the information you need to stay ahead in the game.

Reach out to us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Join our company community on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/783954802>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.